【BCG】Better Measurement, Better Biopharma Marketing.pdf

–Better-than-feared 3Q results

Better profits achieved across 3 business lines

–Better margin outlook, with Bigo to bottom out

Better margins despite cautious sales growth

FY22 results below; GPM recovery on better product mix

Building Better Formal Tvet Systems

Better Results through Learning and Adaptation for a Better World Bank Group

–3Q23 earnings beat on better product mix and record-high GPM

Harnessing the Benefits of Externally Controlled Clinical Trials (ECTs) to Accelerate Development of Better Medicines

China Property Sector–NBS Aug data in-line, expect better recovery in Sep-Oct but sustainability is uncertain